Gliomas occur in 3–4 individuals per 100,000 individuals and are one of the most common primary brain tumors. Treatment options are limited for gliomas despite the progressive nature of the disease. The authors used the Value Driven Outcomes (VDO) database to identify cost drivers and subgroups that are involved in the surgical treatment of gliomas.
A retrospective cohort of patients with gliomas treated at the authors’ institution from August 2011 to February 2018 was evaluated using medical records and the VDO database.
A total of 263 patients with intracranial gliomas met the authors’ inclusion criteria and were included in the analysis (WHO grade I: 2.0%; grade II: 18.5%; grade III: 18.1%; and grade IV: 61.4%). Facility costs were the major (64.4%) cost driver followed by supplies (16.2%), pharmacy (10.1%), imaging (4.5%), and laboratory (4.7%). Univariate analysis of cost contributors demonstrated that American Society of Anesthesiologists physical status (p = 0.002), tumor recurrence (p = 0.06), Karnofsky Performance Scale score (p = 0.002), length of stay (LOS) (p = 0.0001), and maximal tumor size (p = 0.03) contributed significantly to the total costs. However, on multivariate analysis, only LOS (p = 0.0001) contributed significantly to total costs. More extensive tumor resection in WHO grade III and IV tumors was associated with significant improvement in survival (p = 0.004 and p = 0.02, respectively).
Understanding care costs is challenging because of the highly complex, fragmented, and variable nature of healthcare delivery. Adopting effective strategies that would reduce facility costs and limit LOS is likely the most important aspect in reducing intracranial glioma treatment costs.
ABBREVIATIONSASA = American Society of Anesthesiologists; EOR = extent of resection; GBM = glioblastoma; iMRI = intraoperative MRI; KPS = Karnofsky Performance Scale; LOS = length of stay; VDO = Value Driven Outcomes; 5-ALA = 5-aminolevulinic acid.
Alternative Payment Model Framework and Progress Tracking (APM FPT) Work Group: Alternative Payment Model (APM) Framework: Final White Paper2016. Health Care Payment Learning & Action Network(https://hcp-lan.org/workproducts/apm-whitepaper.pdf)[Accessed January 16 2019]
ButenschönVMIlleSSollmannNMeyerBKriegSM: Cost-effectiveness of preoperative motor mapping with navigated transcranial magnetic brain stimulation in patients with high-grade glioma. Neurosurg Focus44(6):E182018
DeWittJCJordanJTFroschMPSamoreWRIafrateAJLouisDN: Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro Oncol19:1640–16502017
EljamelMSMahboobSO: The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ALA, fluorescein, ultrasound and MRI. Photodiagn Photodyn Ther16:35–432016
Institute of Medicine Committeeon the Learning Health Care System in America: Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: The National Academies Press2013
KarsyMBrockAAGuanJBissonEFCouldwellWT: Assessment of cost drivers in transsphenoidal approaches for resection of pituitary tumors using the Value-Driven Outcome Database. World Neurosurg105:818–8232017
McGirtMJChaichanaKLAttenelloFJWeingartJDThanKBurgerPC: Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery63:700–7082008
OstromQTGittlemanHLiaoPVecchione-KovalTWolinskyYKruchkoC: CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol19 (Suppl 5):v1–v882017
StuppRHegiMEMasonWPvan den BentMJTaphoornMJJanzerRC: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol10:459–4662009